Adelene Perkins - Infinity Pharmaceuticals Chairman of The Board, CEO and Pres
INFIDelisted Stock | USD 0.04 0.03 42.86% |
Chairman
Ms. Adelene Q. Perkins serves as Chairman of the Board, Chief Executive Officer of the Company. She was Chairman of the Board, President, Chief Executive Officer of Infinity Pharmaceuticals Inc. She has served as our President and Chief Executive Officer since January 2010, President and Chief Business Officer from October 2008 through December 2009 and as our Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporationrationrate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase business unit. Ms. Perkins has served as a director of the Biotechnology Industry Organization since 2012, a director of Project Hope, a notforprofit social services company since 2013, a director of the Massachusetts Life Sciences Center, a quasipublic agency of the Commonwealth of Massachusetts, since 2014, a director of the Massachusetts Biotechnology Council, a notforprofit organization, since 2014, and a director of Padlock Therapeutics, a privately held biopharmaceutical company since 2015. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain Company, a strategy consulting firm since 2017.
Age | 63 |
Tenure | 7 years |
Professional Marks | MBA |
Phone | 617 453 1000 |
Web | https://www.infi.com |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 9 records | CHAIRMAN Age | ||
Sean DPHIL | CytomX Therapeutics | 57 | |
Hoyoung Huh | CytomX Therapeutics | 47 | |
Ernest Mario | Chimerix | 77 | |
Sumit Mazumder | Instil Bio | 69 | |
Harlan MD | Lyra TherapeuticsInc | 71 | |
Bruce Harker | Instil Bio | N/A | |
MD FACP | Edgewise Therapeutics | 64 | |
William Ringo | Assembly Biosciences | 71 | |
Alan Danson | Instil Bio | N/A |
Management Performance
Return On Equity | -35.21 | |||
Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph Pearlberg, Vice President - Clinical Development | ||
Melissa Hackel, Vice President - Finance | ||
William Bertrand, Executive Vice President General Counsel | ||
Vito Palombella, Chief Scientific Officer and Executive VP | ||
Jeffrey Berkowitz, Independent Director | ||
Seth JD, Chief VP | ||
Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
Norman Selby, Lead Outside Independent Director | ||
Jose Baselga, Independent Director | ||
Samuel Agresta, Chief Medical Officer | ||
Michael Venuti, Independent Director | ||
Stephane Peluso, Chief Officer | ||
MD Ilaria, Chief Officer | ||
Jayne Kauffman, Sr Coordinator | ||
Michael Kauffman, Independent Director | ||
Eric Lander, Independent Director | ||
David Beier, Independent Director | ||
Julian Adams, President of RandD | ||
Anthony Evnin, Independent Director | ||
Gwendolyn Fyfe, Independent Director | ||
Sujay Kango, Executive Vice President Chief Commercial Officer | ||
Ian Smith, Independent Director | ||
Adelene Perkins, Chairman of The Board, CEO and Pres | ||
MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -35.21 | |||
Return On Asset | -0.61 | |||
Operating Margin | (15.70) % | |||
Current Valuation | (9.46 M) | |||
Shares Outstanding | 90.76 M | |||
Shares Owned By Insiders | 2.36 % | |||
Shares Owned By Institutions | 23.48 % | |||
Number Of Shares Shorted | 2.21 M | |||
Price To Earning | (1.63) X | |||
Price To Book | 8.03 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Infinity Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Infinity Pharmaceuticals' short interest history, or implied volatility extrapolated from Infinity Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |